Verastem (VSTM) Non-Current Assets (2011 - 2026)
Verastem (VSTM) recorded quarterly Non-Current Assets of $24.9 million in Q1 2026, up 8.14% quarter-over-quarter from $23.0 million in Q4 2025, and up 255.82% on a YoY basis from $7.0 million in Q1 2025.
Verastem (VSTM) Non-Current Assets (2011 - 2026) Analysis & Trends
Verastem's Non-Current Assets history runs 16 years deep, the most recent figure standing at $24.9 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 255.82% year-over-year to $24.9 million; the TTM figure through Mar 2026 stood at $92.7 million (up 265.14% YoY), while the FY2025 annual figure was $23.0 million, up 250.14% from the prior year.
- Non-Current Assets was $24.9 million for Q1 2026 at Verastem, up from $23.0 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $24.9 million in Q1 2026 to a low of $1.7 million in Q3 2023.
- Historically, Non-Current Assets has averaged $8.5 million across 5 years, with a median of $5.9 million in 2024.
- The sharpest annual moves came in 2022 and 2025: Non-Current Assets sank 72.25% in 2022, then soared 298.81% in 2025.
- A 5-year view of Non-Current Assets shows it stood at $2.2 million in 2022, then surged by 176.88% to $6.0 million in 2023, then grew by 8.96% to $6.6 million in 2024, then surged by 250.14% to $23.0 million in 2025, then rose by 8.14% to $24.9 million in 2026.
- The last three Non-Current Assets figures came in at $24.9 million (Q1 2026), $23.0 million (Q4 2025), and $22.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 62,953.78 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 30.30 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 39.71 Mn |
| 10 | Verastem | 407.42 Mn | 225.74 Mn | 15.90 Mn | 24.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.90 Mn |
| Dec 31, 2025 | 23.03 Mn |
| Sep 30, 2025 | 22.80 Mn |
| Jun 30, 2025 | 21.99 Mn |
| Mar 31, 2025 | 7.00 Mn |
| Dec 31, 2024 | 6.58 Mn |
| Sep 30, 2024 | 5.72 Mn |
| Jun 30, 2024 | 6.10 Mn |
| Mar 31, 2024 | 5.87 Mn |
| Dec 31, 2023 | 6.04 Mn |
| Sep 30, 2023 | 1.67 Mn |
| Jun 30, 2023 | 1.80 Mn |
| Mar 31, 2023 | 1.98 Mn |
| Dec 31, 2022 | 2.18 Mn |
| Sep 30, 2022 | 2.34 Mn |
| Jun 30, 2022 | 2.53 Mn |
| Mar 31, 2022 | 2.71 Mn |
| Dec 31, 2021 | 2.92 Mn |
| Sep 30, 2021 | 3.12 Mn |
| Jun 30, 2021 | 9.13 Mn |